SCHEMBL5078191

SCHEMBL5078191

COc1ccc(C(=O)Oc2ccc(C(=O)O)cc2)cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 8/20 0.67
RARB P10826 7/20 0.67
RARG P13631 7/20 0.67
KMT2A Q03164 4/20 0.67
MEN1 O00255 3/20 0.67
NR1I2 O75469 1/20 0.67
LMNA P02545 1/20 0.67
PGR P06401 1/20 0.67
HSPD1 P10809 1/20 0.67
GOT1 P17174 1/20 0.67
GLRA1 P23415 1/20 0.67
BLM P54132 1/20 0.67
HSPE1 P61604 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
IKBKB O14920 3/20 0.48
S1PR1 P21453 1/20 0.48
HDAC11 Q96DB2 2/20 0.47
HDAC2 Q92769 1/20 0.47
THRB P10828 1/20 0.46
RECQL P46063 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9699416 0.92 RARA (0.64) RARARARBRARGKMT2AMEN1
SCHEMBL8461975 0.92 RARA (0.61) RARARARBRARGKMT2AMEN1
SCHEMBL8459188 0.91 KMT2A (0.57) RARARARBRARGKMT2AMEN1
SCHEMBL9127710 0.91 KMT2A (0.57) RARARARBRARGKMT2AMEN1
SCHEMBL8432481 0.91 RARB (0.57) RARARARBRARGKMT2AMEN1
SCHEMBL9126386 0.90 RARA (0.58) RARARARBRARGKMT2AMEN1
SCHEMBL30287880 0.90 RARA (0.55) RARARARBRARGKMT2AMEN1
SCHEMBL9127200 0.89 RARA (0.57) RARARARBRARGKMT2AMEN1
SCHEMBL9493293 0.89 KMT2A (0.56) RARARARBRARGKMT2AMEN1
SCHEMBL9124257 0.89 RARA (0.65) RARARARBRARGKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020068665-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2020-04-02 WO claimed
US-5556844-A SYNERGISTIC, SKIN DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1996-09-17 US claimed
EP-0465343-B1 Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association CIRD GALDERMA (FR) 1994-06-15 EP claimed
EP-0325540-B1 AROMATIC ESTERS AND THIOESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN OR ANIMAL THERAPEUTICS AND IN COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1993-04-14 EP claimed
US-4925658-A TREATMENT OF DERMATOLOGIC, RHEUMATIC, RESPIRATORY, OPHTHALMOLOGIC DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) 1990-05-15 US claimed
EP-0325540-A1 Aromatic esters and thioesters, process for their preparation and their use in human or animal therapeutics and in cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1989-07-26 EP claimed
JP-2009841-A None JP disclosed
US-20210338558-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2021-11-04 US disclosed
WO-2020068665-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN FABIUS BIOTECHNOLOGY (US) 2020-04-02 WO disclosed
US-20080255244-A1 Administering a Calmodulin-dependent protein kinase (M kinase II) gamma inhibitor; acute myelogenous leukemia, chronic myelogenous leukemia, gastrointestinal stromal tumor, small cell lung cancer, non-small cell lung cancer, ovarian cancer FRED HUTCHINSON CANCER RESEARCH CENTER 2008-10-16 US disclosed
US-5587367-A SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1996-12-24 US disclosed
US-5556844-A SYNERGISTIC, SKIN DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1996-09-17 US disclosed
EP-0325540-B1 AROMATIC ESTERS AND THIOESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN OR ANIMAL THERAPEUTICS AND IN COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1993-04-14 EP disclosed
US-5173289-A Skin disorders, antiinflammatory agents CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) 1992-12-22 US disclosed
US-4925658-A TREATMENT OF DERMATOLOGIC, RHEUMATIC, RESPIRATORY, OPHTHALMOLOGIC DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (CIRD) (FR) 1990-05-15 US disclosed
JP-H029841-A AROMATIC ESTER AND THIOESTER CENTRE INTERNATL RECH DERMATROLOG (CIRD) 1990-01-12 JP disclosed
EP-0325540-A1 Aromatic esters and thioesters, process for their preparation and their use in human or animal therapeutics and in cosmetics CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1989-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338558-A1 USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN COL14A1, COL2A1, COL1A1 RARA 1211/4885RARB 987/4885RARG 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.